How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.

We break down the latest developments in the consumer-retail sector, including Amazon earnings, the $1.4 billion Jimmy Choo buyout, and the turnaround prospects for Target.

Get $25 off your first purchase at http://bombfell.com/fool.

We break down the latest developments in the consumer-retail sector, including Amazon earnings, the $1.4 billion Jimmy Choo buyout, and the turnaround prospects for Target.

Get $25 off your first purchase at http://bombfell.com/fool.

Before you follow an advisor's advice on these topics, make sure you know the whole story.

Before you follow an advisor's advice on these topics, make sure you know the whole story.

New quarterly numbers from Alphabet and Facebook sent the stocks in different directions -- why did the Street love one set of estimate-beating numbers and not the other?

New quarterly numbers from Alphabet and Facebook sent the stocks in different directions -- why did the Street love one set of estimate-beating numbers and not the other?

Fossil fuels may be critical today, but that fact is changing at an accelerated rate.

Fossil fuels may be critical today, but that fact is changing at an accelerated rate.

Hunting for new small cap stocks to watch? We've got you covered. In today's show, we discuss how NovoCure, Flexion Therapeutics, and Zogenix want to shake-up healthcare.